LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

Search

Axsome Therapeutics Inc

Chiusa

SettoreSettore sanitario

100.15 -2.25

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

100.15

Massimo

100.87

Metriche Chiave

By Trading Economics

Entrata

15M

-59M

Vendite

2.7M

121M

EPS

-1.216

Margine di Profitto

-48.914

Dipendenti

712

EBITDA

14M

-57M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+78% upside

Dividendi

By Dow Jones

Utili prossimi

4 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-346M

5.1B

Apertura precedente

102.4

Chiusura precedente

100.15

Notizie sul Sentiment di mercato

By Acuity

4%

96%

2 / 381 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Axsome Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 giu 2025, 18:52 UTC

Utili

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

20 giu 2025, 16:15 UTC

Acquisizioni, Fusioni, Takeovers

Canadian Natural Selling Control of Gas Plant to Secure Approval for Schlumberger Deal

21 giu 2025, 08:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

21 giu 2025, 08:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

21 giu 2025, 08:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

20 giu 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

20 giu 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

20 giu 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

20 giu 2025, 20:13 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 giu 2025, 20:11 UTC

Discorsi di Mercato

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20 giu 2025, 19:56 UTC

Discorsi di Mercato

Crude Oil Slips to End Week -- Market Talk

20 giu 2025, 18:35 UTC

Discorsi di Mercato

Warehouse Clubs Seen Growing Market Share -- Market Talk

20 giu 2025, 18:12 UTC

Discorsi di Mercato

Gold Slides to Close Shortened Week -- Market Talk

20 giu 2025, 17:56 UTC

Discorsi di Mercato

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20 giu 2025, 17:50 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 giu 2025, 17:35 UTC

Acquisizioni, Fusioni, Takeovers

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20 giu 2025, 17:30 UTC

Discorsi di Mercato
Utili

Adobe's AI Headwinds Seen Fading -- Market Talk

20 giu 2025, 17:03 UTC

Utili

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20 giu 2025, 16:50 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

20 giu 2025, 16:50 UTC

Discorsi di Mercato
Utili

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20 giu 2025, 16:44 UTC

Acquisizioni, Fusioni, Takeovers

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20 giu 2025, 16:40 UTC

Discorsi di Mercato
Utili

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

20 giu 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

20 giu 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

20 giu 2025, 16:17 UTC

Acquisizioni, Fusioni, Takeovers

UniCredit: ULI and UVA Are Expected to Merge in 2026

20 giu 2025, 16:17 UTC

Acquisizioni, Fusioni, Takeovers

UniCredit: Alessandro Santoliquido has been appointed CEO of both companies alongside his role as Head of Group Insurance

20 giu 2025, 16:05 UTC

Discorsi di Mercato

Gold Futures on Track to End Week Lower Despite Haven Demand -- Market Talk

20 giu 2025, 15:56 UTC

Discorsi di Mercato
Utili

Accenture Says Federal Business Had Immaterial Impact to Growth -- Market Talk

20 giu 2025, 15:26 UTC

Discorsi di Mercato

Natural Gas Slips After Streak of Higher Closes -- Market Talk

20 giu 2025, 15:25 UTC

Acquisizioni, Fusioni, Takeovers

Regulator Says Satisfied Sale Would Preserve Competition in Area Around Seiu Processing Plant

Confronto tra pari

Modifica del prezzo

Axsome Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

78% in crescita

Previsioni per 12 mesi

Media 179.23 USD  78%

Alto 210 USD

Basso 148 USD

Basato su 16 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Axsome Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

16 ratings

16

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

107.24 / 112.29Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Neutral Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

2 / 381 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.